Tsagkli Panagiota, Geropeppa Maria, Papadatou Ioanna, Spoulou Vana
Immunobiology and Vaccinology Research Laboratory and Infectious Diseases Department "MAKKA", First Department of Paediatrics, "Aghia Sophia" Children's Hospital, Athens Medical School, 11527 Athens, Greece.
Vaccines (Basel). 2024 Sep 14;12(9):1051. doi: 10.3390/vaccines12091051.
The emergence of SARS-CoV-2 led to a global health crisis and the burden of the disease continues to persist. The rapid development and emergency authorization of various vaccines, including mRNA-based vaccines, played a pivotal role in mitigating severe illness and mortality. However, rapid viral mutations, leading to several variants of concern, challenged vaccine effectiveness, particularly concerning immune evasion. Research on immunity, both from natural infection and vaccination, revealed that while neutralizing antibodies provide protection against infection, their effect is short-lived. The primary defense against severe COVID-19 is derived from the cellular immune response. Hybrid immunity, developed from a combination of natural infection and vaccination, offers enhanced protection, with convalescent vaccinated individuals showing significantly higher levels of neutralizing antibodies. As SARS-CoV-2 continues to evolve, understanding the durability and breadth of hybrid immunity becomes crucial. This narrative review examines the latest data on humoral and cellular immunity from both natural infection and vaccination, discussing how hybrid immunity could inform and optimize future vaccination strategies in the ongoing battle against COVID-19 and in fear of a new pandemic.
严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的出现引发了全球健康危机,该疾病的负担持续存在。包括基于信使核糖核酸(mRNA)的疫苗在内的各种疫苗的快速研发和紧急授权,在减轻重症和死亡率方面发挥了关键作用。然而,病毒的快速变异导致了几种值得关注的变异株,对疫苗的有效性构成了挑战,尤其是在免疫逃逸方面。对自然感染和疫苗接种所产生免疫的研究表明,虽然中和抗体能提供抗感染保护,但其作用是短暂的。针对重症冠状病毒病(COVID-19)的主要防御来自细胞免疫反应。由自然感染和疫苗接种相结合产生的混合免疫提供了更强的保护,康复后接种疫苗的个体显示出显著更高水平的中和抗体。随着SARS-CoV-2不断进化,了解混合免疫的持久性和广度变得至关重要。这篇叙述性综述审视了自然感染和疫苗接种所产生体液免疫和细胞免疫的最新数据,讨论了在持续抗击COVID-19以及预防新的大流行的过程中,混合免疫如何为未来的疫苗接种策略提供参考并使其优化。